Point Biopharma, a wholly owned subsidiary of Eli Lilly and Company

A radiopharmaceutical company developing targeted cancer therapies, owned by Eli Lilly.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.